Prednisolone and Primary myelofibrosis - a phase IV clinical study of FDA data

Summary:

Primary myelofibrosis is found among people who take Prednisolone, especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Prednisolone and have Primary myelofibrosis. It is created by eHealthMe based on reports of 198,532 people who have side effects when taking Prednisolone from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 04, 2023

198,532 people reported to have side effects when taking Prednisolone.
Among them, 142 people (0.07%) have Primary myelofibrosis.

What is Prednisolone?

Prednisolone has active ingredients of prednisolone. It is often used in rheumatoid arthritis. eHealthMe is studying from 182,068 Prednisolone users for its effectiveness, alternative drugs and more.

What is Primary myelofibrosis?

Primary myelofibrosis (primary disorder of the bone marrow) is found to be associated with 1,094 drugs and 790 conditions by eHealthMe.

Number of Prednisolone and Primary myelofibrosis reports submitted per year:

Could Prednisolone cause Primary myelofibrosis?

* Approximation only. Some reports may have incomplete information.

Do you take Prednisolone and have Primary myelofibrosis?

Check whether Primary myelofibrosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Abdullah, D., Mohamed, A. M. F. S., & Liew, A. K. C., "Dentine hypersensitivity-like tooth pain associated with the use of high-dose steroid therapy", Journal of conservative dentistry: JCD, 2018 Jan .

Related studies

How severe was Primary myelofibrosis and when was it recovered:

Primary myelofibrosis in Prednisolone

Expand to all the drugs that have ingredients of prednisolone:

Primary myelofibrosis and drugs with ingredients of prednisolone (138 reports)

Alternative drugs to, pros and cons of Prednisolone:

Prednisolone (182,068 reports)

Common Prednisolone side effects:

Fever: 10,764 reports
Pneumonia: 9,340 reports
Drug ineffective: 8,974 reports
Breathing difficulty: 7,519 reports
Diarrhea: 7,028 reports
Rashes (redness): 6,528 reports
Thrombocytopenia (decrease of platelets in blood): 6,401 reports

Browse all side effects of Prednisolone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Primary myelofibrosis treatments and more:

Primary myelofibrosis (35,060 reports)

COVID vaccines that are related to Primary myelofibrosis:

Common drugs associated with Primary myelofibrosis:

All the drugs that are associated with Primary myelofibrosis:

Primary myelofibrosis (1,094 drugs)

Common conditions associated with Primary myelofibrosis:

High blood pressure: 141 reports
Idiopathic thrombocytopenic purpura (itp): 108 reports

All the conditions that are associated with Primary myelofibrosis:

Primary myelofibrosis (790 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on prednisolone (the active ingredients of Prednisolone) and Prednisolone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.